Opinion|Videos|November 14, 2024
Key Considerations for Genetic Testing Selection in Pediatric Patients with Epilepsy
Author(s)John Michael Schreiber, MD, FAES
Key Takeaways
- Genetic testing is vital for diagnosing epilepsy with a suspected genetic basis, especially in early-onset or treatment-resistant cases.
- Pediatric genetic test selection considers age, clinical presentation, and family history, ensuring appropriate test choice.
John Michael Schreiber, MD, expands on the role of genetic testing in identifying and diagnosing epilepsy, discussing when it is clinically indicated and who should receive it, while also addressing key considerations for selecting tests for pediatric patients based on individual presentations and clinical factors, and outlining how to choose the best testing options while recognizing potential barriers and expectations for health care providers, caregivers, and patients before and after testing.
Advertisement
Episodes in this series
- Please expand on the role of genetic testing in epilepsy identification and diagnosis.
- When is genetic testing clinically indicated, and who is best suited to receive genetic testing?
- Please discuss key considerations when selecting genetic tests for pediatric patients with epilepsy.
- How does a patient’s presentation and other clinical factors influence your decision-making?
- Please outline how you choose the best testing option for patients. What, if any, barriers exist?
- What should HCPs, caregivers, and patients expect before and after the test?
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Williams, MD, is joined by Marcus Gates, MD, and they discuss recognizing cervical nerve root and spinal cord compression, navigating treatment options, and determining when surgery may be appropriate.
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.
An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.
The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.
Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.
IJMSC editor-in-chief, François Bethoux, MD, and colleagues cover idea generation, poster conversion, literature reviews, and peer review in a 4-part webinar series for MS clinicians.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS
2
PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS
3
Sevasemten Misses Primary Endpoint in Pivotal Trial for Becker Muscular Dystrophy
4
Gray Areas: Is Preventing Frailty in Multiple Sclerosis a Realistic Goal?
5